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Abstract
Background: Induced sputum (IS) has been proposed as a non-invasive alternative to bronchoalveolar lavage (BAL) for the
assessment and monitoring of airways inflammation. The aim of this study was to compare both methods in patients with cystic
fibrosis (CF). The possible differences between subjects with CF, mild asthma and healthy volunteers (HV) was also assessed.
Method: In a single centre, randomised, two way crossover study, 11 patients with CF, 9 mild asthmatics (MA) and 11 HV
underwent BAL and hypertonic saline induction on consecutive days. Free neutrophil elastase (NE), neutrophil elastaseya -anti-1
trypsin complex (NE–AAT), tumour necrosis factor receptor (p55) and interleukin-8 (IL-8) were measured in cell free
supernatants. Results: Three CF patients reported serious adverse events following BAL. NE was usually undetectable in both IS
or BAL samples and NE–AAT concentrations did not differ consistently between the two sampling methods. IL-8 and p55 levels
in the CF patients tended to be higher in IS samples compared with BAL samples (median 19 860 vs. 3855 pgyml and 2.55 vs.
0.29 ngyml, respectively). There was a significant difference in mean p55 concentrations between CF, MA and HV in IS samples
(Ps0.003) but not in BAL samples (Ps0.36). The difference in mean IL-8 concentrations in IS samples between subject groups
was statistically different (Ps0.023). Conclusions: IS samples can be safely obtained from CF patients. Analysis of IS samples
can help to characterize the inflammatory process in the airways of CF patients. The serious adverse events following BAL in 3
CF patients highlight an inherent risk associated with this procedure.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In patients with cystic fibrosis (CF) it is important to
establish safe methods for the collection of airway
specimens suitable for the assessment of disease activity
and response to treatment. Not all patients with CF
expectorate sputum spontaneously and certainly not in
a reproducible manner. Bronchoalveolar lavage (BAL)
has been used to sample airway fluid in CF patients and
has enabled the measurement and evaluation of a range
of proinflammatory mediators and cytokines considered
important in the pathogenesis of injury in CF w1x. It is
invasive and as sampling tends to be localised it may
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not reflect the inflammatory processes in the lung
generally. Induced sputum (IS) has recently been studied
in children with CF w2x. It appears a less invasive
method to obtain samples, which may also better reflect
the inflammatory processes in the airways w3x.
It is unclear whether IS or BAL would be best suited
for monitoring disease activity in patients with CF. The
aim of this study was to compare these two methods of
airway sampling in adult patients with CF.
2. Methods
2.1. Patient recruitment
Eleven patients with CF, 9 patients with mild asthma
(MA) and 11 healthy volunteers (HV) were included in
the study. All subjects were aged 18 years or older and
had provided written informed consent. The study was
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approved by the Research Ethics Committee of the
Faculty of Medicine, The Queen’s University of Belfast.
2.1.1. Cystic fibrosis
The diagnosis was confirmed in childhood (sweat
Na and Cl )70 mmolyl) and all patients wereq y
chronically infected with Pseudomonas aeruginosa,
Staphlococcus aureus, Haemophilus influenzae or Burk-
holderia cepacia and had mild impairment of lung
function (FEV )70% of predicted value).1
2.1.2. Mild asthma
Patients with a history of recurrent wheezing and
dyspnoea with mild impairment of lung function
(FEV )70% of predicted value).1
2.1.3. Healthy volunteers
No evidence of clinically important medical disease
and no history of upper respiratory tract infection in the
preceding 2 weeks.
2.2. Exclusion criteria
CF patients and MA were excluded from the study if
resting hypoxaemia (arterial oxygen saturation wSpO x-2
92%) was evident on breathing room air or there had
been an exacerbation of disease within the previous 30
days. All the CF and MA subjects were lifetime non-
smokers and any HV who were current smokers or ex-
smokers of -6 months were excluded from the study.
2.3. Study design
The design was a single centre randomised two way
crossover study over 2 days with MA and HV serving
as positive and negative controls, respectively. Following
recruitment to the study, baseline assessment was per-
formed with measurement of height and weight, together
with obtaining venous blood samples for total white
blood cell count (WCC), urea, electrolytes and creati-
nine and C-reactive protein (CRP) and sputum samples
for microbiology. Patients and controls were then ran-
domised into sequence groups for the collection of
airway samples on consecutive days.
2.4. Bronchoscopy and bronchoalveolar lavage
All bronchoscopies were performed using a standard
protocol w4x. BAL was performed (4=30 ml aliquots of
sterile isotonic saline, right middle lobe). The returned
samples were pooled, placed immediately on ice, taken
to the laboratory and processed as described below.
2.5. Induced sputum
FEV and forced vital capacity (FVC) were recorded1
using a vitalograph (Vitalograph, UK). Following this,
two puffs (200 mg) of salbutamol were administered
via a metered dose inhaler. Ten minutes later, sputum
induction using 3% saline was performed using a de-
Vilbiss 2000 ultrasonic nebuliser with an output of 2.4
ml and an aerodynamic mass median diameter of 4.5
mm. After each period of nebulisation, spirometry was
repeated and if the FEV fell by more than 20% of the1
pre-saline value or the subject became symptomatic in
any way the inhalation was terminated. All sputum
produced during nebulisation was retained in a sterile
container at room temperature.
2.6. Processing of samples
2.6.1. Bronchoalveolar lavage
An aliquot of the pooled BAL sample was removed
for total cell count using an improved Neubauer hae-
mocytometer and differential cell counts using the glass
coverslip method w5x. The remaining BAL fluid was
centrifuged (200=g, 10 min, 4 8C) after which the
supernatant was removed and volume of supernatant
and weight of pellet recorded. The supernatant was
aliquoted and stored at y70 8C until assayed.
2.6.2. Induced sputum
Sputum was processed essentially using the method
of Pavord et al. w6x. Sputum plugs were selected from
the original known weight of IS, to minimise salivary
contamination. The plugs were weighed, and 4 times
the selected sputum volume of freshly prepared 0.1%
(wyv) dithiothreitol (DTT) was added. After vortexing
(15 s) and gentle mixing, samples were incubated in a
shaking water bath at 37 8C for 15 min. Subsequently,
a further 4 volumes of phosphate buffered saline (PBS)
were added and incubated for a further 5 min. The
resultant suspension was filtered through 53-mm gauze
(Lockertex, Warrington, England), and centrifuged at
200=g for 10 min. The supernatant was removed and
protease inhibitors added. For interleukin-8 (IL-8), neu-
trophil elastaseya -anti-trypsin complex (NE–AAT)1
complexes and p55 soluble TNF receptors, 3.7 mM
EDTA (inhibiting metalloproteinase-like activity) (Sig-
ma Chemicals, Poole, England), 150 mM TLCK (inhib-
iting trypsin-like activity) (Sigma Chemicals), 20 mM
Z-Phe-diphenylphosphonate (inhibiting chymotrypsin-
like activity) (supplied by the Biomolecular Sciences
Group, School of Pharmacy, Queen’s University of
Belfast) and 100 mM methoxysuccinyl–Ala–Ala–Pro–
Val–chloromethylketone (Sigma Chemicals) were added
(final concentrations shown). For NE, all protease inhib-
itors, except methoxysuccinyl–Ala–Ala–Pro–Val–chlo-
romethylketone (NE inhibitor) were added in final
concentrations as stated.
271L.P.A. McGarvey et al. / Journal of Cystic Fibrosis 1 (2002) 269–275
Table 1
Demographic features of study patients
Subject group M:F Age Height Weight FEV (% predicted)1
(n) (years) (cm) (kg) Median (range)
CF (11) 9:2 22.7 (3.8) 169.5 (8.2) 63.5 (11.9) 76.0 (70.0–94.0)
MA (9) 5:4 24.1 (3.9) 76.8 (14.9) 74.5 (20.5) 85.0 (70.0–96.0)
HV (11) 6:5 24.3 (2.8) 172.4 (7.2) 72.5 (9.6) 100.5 (91.0–115.0)
CF, cystic fibrosis; MA, mild asthmatic; HV, healthy volunteer; M, male; F, female; FEV , Forced expiratory volume in 1 s. Values given as1
mean (S.D.) unless otherwise stated.
2.7. Assays
2.7.1. Free human neutrophil elastase
This was measured in IS or BAL using a kinetic,
chromogenic microtitre plate assay using succinyl–Ala–
Ala–Pro–Val–p–nitroanalide (Bachem) as a substrate.
A standard curve, constructed from known concentra-
tions of purified elastase, was included in each assay.
Sputum or BAL samples were assayed at an initial
dilution of 1:20 (100 ml) and the reaction initiated by
the addition of substrate (100 ml of a 2 mgyml solution
gave a final concentration of 1 mgyml). Hydrolysis of
the substrate was monitored at 405 nm commenced
immediately and at 1 min intervals for 40 min, during
which the plate was maintained at 37 8C. The maximum
change in OD per minute (V ) was derived usingmaxymin
BIOLISE software, and the corresponding elastase con-
centration was determined from the standard curve. The
limit of quantification for the assay was 0.004 unitsyml.
Intra-assay and inter-assay coefficients were 4.5 and
8.2%, respectively.
2.7.2. Human neutrophil elastase complexed to a anti-1
trypsin
This was quantified by an enzyme-linked immuno-
sorbent assay (ELISA). Briefly, microtitre plates were
coated with anti-human neutrophil AAT IgG (The Bind-
ing Site, Birmingham, England) and the plate incubated
overnight at 4 8C. Any unbound sites were blocked
using a solution of 10% (w:v) Marvel (Premier Bever-
ages, Adbaston, England) in PBS (200 mlywell) for 1
h at 37 8C. The plate was then washed briefly with
PBS. A stock calibrant was prepared by mixing NE
(Calbiochem, CN Biosciences UK, Nottingham, Eng-
land) and a -antitrypsin (Calbiochem) to constitute a1
final concentration of NE–AAT complex of 20 mgyml.
The calibration curve was prepared by diluting the stock
calibrant with 5% (w:v) Marvel in PBS to give a
working solution of 4000 ngyml. Fivefold serial dilu-
tions were made until a concentration of 0.256 ngyml
was reached. Standards, IS and BAL samples were
plated out in duplicate and incubated for 2 h at 37 8C.
The NE–AAT complex was detected using a peroxidase-
labelled sheep anti-human HE IgG (The Binding Site)
for 2 h at 37 8C and a ready to use solution of 3,39,5,59-
Tetramethylbenzidine (Calbiochem). Absorbance was
measured at 450 nm on a SpectraThermo microtitre
plate reader (Tecan, Reading, UK). Any sample dupli-
cates with coefficient of variation greater than 10% were
repeated. The detection limit for the assay was 5 ngy
ml. Intra-assay and inter-assay coefficients of variation
were 4.6 and 7.2%, respectively.
2.7.3. Interleukin-8
IL-8 levels were measured in sputum and BAL
supernatant using a commercially available ELISA
(R&D Systems, Abingham, Oxon, UK). The limit of
quantification for the assay was 312 pgyml. Intra-assay
and inter-assay coefficients of variation were 5.6 and
7.4%, respectively.
2.7.4. p55 soluble TNF receptor
p55 receptors were measured by a sandwich ELISA
w7x. Briefly, microtitre plates were coated with SR13
monoclonal antibody to soluble p55 overnight at room
temperature. Blocking was achieved using 1% (wyv)
bovine serum albumin. Samples and standards were
incubated for 1 h, and p55 identified with biotinylated
5R5-monoclonal antibody in combination with strepav-
idin–peroxidase conjugate. Absorbance was measured
at 450 nm. The assay had a detection limit of 0.5 ngy
ml. Intra-assay and inter-assay coefficients of variation
were 5.8 and 8.4%, respectively.
2.8. Statistics
Data are reported as median (range) unless otherwise
stated. The BAL and sputum biochemical analyses were
compared between the three groups using a one-way
analysis of variance (ANOVA). Where an individual
measurement was below the detection limit for the assay,
the value was assumed to be equal to the detection limit
when the data were summarised. Correlations were
tested using Spearman’s rank method. A value of P-
0.05 was considered significant.
3. Results
3.1. Subject characteristics
Subject characteristics are summarized in Table 1.
The bacterial pathogens cultured from sputum samples
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Table 2
Organisms isolated from sputum samples
Pathogen Number
Pseudomonas aeruginosa 8
Burkholderia cepacia 5
Haemolytic streptococcus 2
Haemophilus influenzae 2
Streptococcus pneumoniae 1
Staphylococcus aureus 1
Moraxella catarrhalis 1
Fig. 1. Concentration of IL-8 and p55 levels in IS and BAL specimens
from CF patients. Definition of abbreviations IL-8, interleukin-8; p55,
Tumour necrosis factor-alpha receptor; IS, induced sputum; BAL,
bronchoalveolar lavage; CF, cystic fibrosis.
Table 3
Concentrations of cells, E and AAT-E in samples obtained by bronchoscopy and IS from 11 CF patients, 9 mild asthmatic patients and 11 HV
CF MA HV
(ns11) (ns9) (ns11)
BAL
Total cells=10 ml4 y1 62.9 (14–113) 25.5 (6–83) 16.5 (10–23)
Macrophage 43.7 (2.4–91.0) 59.1 (32.8–81.4) 86.6 (68.3–93.8)
Neutrophils 38.7 (1.5–96.5) 2.33 (0.2–7.4) 7.5 (0.6–25.1)
Lymphocyte 0.6 (0.1–0.9) 0.7 (0.1–1.3) 0.7 (0.25–0.9)
Eosinophils 0.18 (0–0.7) 4.3 (0–16.1) 0.5 (0–1.7)
Epithelial 4.95 (0.1–15.4) 29.5 (4.5–58.7) 4.7 (2.5–7.4)
Recovery (%) 33.8 (17–50) 32.8 (21–50) 50.9 (33–75)
IS
E (unitsyml) 0.018 (0.004–0.023) -0.004 -0.004
NE–AAT (mgyl) 0.281 (0.076–74.13) 0.08 (0.025–1.17) 0.381 (0.004–12.62)
BAL
E (unitsyml) 0.004 (0.004–0.99) -0.004 -0.004
NE–AAT (mgyl) 10.60 (0.001–10 000) 0.001 (0–0.056) 0.005 (0–0.009)
CF, cystic fibrosis; MA, mild asthmatic; HV, healthy volunteer; BAL, bronchoalveolar lavage; IS, induced sputum; E, free human neutrophil
elastase activity; NE–AAT, neutrophil elastaseya -anti-trypsin complex. Values given as mean (range).1
are displayed in Table 2. Ten of the 11 patients with CF
had a history of infection with no organisms cultured
from the asthmatic or healthy subjects. No significant
difference in either total cell counts or neutrophil per-
centage in BAL was observed when B. cepacia positive
and negative patients were compared. There was no
significant correlation between percentage of neutrophils
and lung function parameters (FEV , FVC).1
3.2. Free human elastase (NE)
Regardless of the method of collection, NE activity
was below the limit of quantification in the majority of
samples (11 of 19) from patients with CF. There was
no clear pattern in the relative activities in samples
collected by different methods. All BAL and IS samples
collected from MA and HV had undetectable free
elastase levels.
3.3. Elastase complexes (NE–AAT)
Concentration of NE–AAT complexes in samples
collected by the two different methods from CF patients
varied widely. However, the mean concentrations in both
BAL and IS samples from patients with CF were greater
than the corresponding samples from patients with MA
or HV (Table 3).
3.4. p55 (TNFa receptor)
There was less variability in the p55 concentrations
in IS and BAL samples from patients with CF. In CF
patients, concentrations of p55 were consistently greater
in IS samples compared to those obtained from BAL
(median IS concentration, 2.55 ngyml (range: 0.93–
6.71 ngyml) vs. median BAL concentration 0.29 ngyml
(range: 0.10–1.24 ngyml)) (Fig. 1). Median concentra-
tions in samples collected by IS differed significantly
between patients with CF, patients with MA (1.74 ngy
ml (range: 0.53–3.57 ngyml)) and HV (0.20 ngyml
(range: 0.13–0.37 ngyml)), Ps0.003, (Fig. 2). How-
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Fig. 2. p55 levels in IS from patients with CF (ns7), MA (ns6)
and HV (ns9). p55, tumour necrosis factor-alpha receptor; IS,
induced sputum; CF, cystic fibrosis; MA, mild asthmatic; HV, healthy
volunteer; ANOVA, analysis of variance.
Fig. 3. IL-8 levels in IS from patients with CF (ns8), MA (ns7)
and HV (ns7). IL-8, interleukin-8; IS, induced sputum; CF, cystic
fibrosis; MA, mild asthmatic; HV, healthy volunteer; ANOVA, anal-
ysis of variance.
ever, no significant difference was noted in p55 concen-
trations between CF patients and BAL samples from
MA and HV subjects. There was no correlation between
p55 concentrations measured in BAL or IS from patients
with CF (Ps0.584).
3.5. Interleukin-8
Among patients with CF, IL-8 concentrations tended
to be greater in the IS samples than in the BAL samples
(median IS concentration 19 860 pgyml (range: 1439–
59 847 pgyml) vs. median BAL concentration 3855 pgy
ml (range:-312–13 246 pgyml)) (Fig. 1). The median
IL-8 concentrations in IS from CF patients, patients with
MA (5215 pgyml (range: -713–14 155 pgyml)) and
HV (5379 pgyml (range: -312–37 260 pgyml)), dif-
fered significantly (Ps0.023, Fig. 3). IL-8 concentra-
tions were undetectable in all the BAL samples from
subjects with MA and HV. There was no between IL-8
concentrations measured in BAL or IS from patients
with CF (rs0.464, Ps0.302).
3.6. Differential cell counts
The differential cell counts in BAL for the three
subject groups are shown in Table 2. As anticipated,
neutrophil counts were significantly increased in the
lavage specimens from CF patients compared with the
MA and HV groups. Eosinophil numbers were increased
in the MA group compared with CF and HV. There was
no significant correlation between neutrophil percentages
and IL-8 levels.
3.7. Adverse events
3.7.1. Induced sputum
All subjects tolerated the IS well. There was no
significant reduction in FEV during or following spu-1
tum induction in any of the subjects (data not shown).
3.7.2. Bronchoalveolar lavage
Adverse events were reported for 3 patients with CF,
all resulting in prolonged hospitalisation.
Event 1: A 22-year-old male with CF who had B.
cepacia isolated from sputum was enrolled in the study.
At this time CRP was -1 mgyml and WCC was
8=10 cellsyl. He was randomised to undergo IS on9
day 1, after which no adverse events were reported. He
had BAL performed the following day during which he
became hypoxic (SpO s82%). Shortly after he devel-2
oped a pyrexia and his temperature remained high for 5
days. WCC and CRP increased to 22=10 cellsyl and9
152 mgyml, respectively and took some weeks to
normalise.
Event 2: A 31-year-old male with CF, who had
Streptococcus pneumoniae isolated from sputum on the
first day of the study, developed shortness of breath
shortly after BAL. A CXR was performed, and demon-
strated new changes of increased shadowing in the right
mid zone. The symptoms persisted for 48 h.
Event 3: A 19-year-old male with CF, with B. cepacia
and Pseudomonas aeruginosa previously isolated from
sputum enrolled in the study and underwent IS without
complication. However, 8 h after BAL he developed a
severe pyrexia which lasted for 16 h and required an
overnight stay in hospital.
4. Discussion
In this study we have demonstrated that biochemical
markers of inflammation can be measured in IS samples
from patients with CF. There was wide inter-patient
variability in mediator levels within the different groups,
possibly due to the relatively small number of subjects
studied. IS appears to provide a sample more highly
concentrated in inflammatory mediators than BAL. In
addition, there were a number of serious adverse events
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following BAL highlighting the inherent risks associated
with this procedure in CF patients.
Higher concentrations of IL-8 and p55 were consis-
tently measured in the IS samples compared with BAL.
It is likely that the technique of IS samples the proximal
airways where most of the airway secretions are concen-
trated w3x, whereas BAL fluid reflects events in the
distal airways. Further dilution of cell and mediator
levels by the saline lavage is likely to be greater than
dilution caused by hypertonic saline during sputum
induction. The demonstration of a more concentrated
sample obtained with IS compared to that recovered at
bronchoscopy has been reported in studies involving
asthmatics and COPD patients w8,9x. However, as medi-
ator concentrations were undetectable in the BAL sam-
ples from a number of the MA and healthy controls,
our results need to be interpreted with caution.
Unfortunately, we are unable to report on cell differ-
entials for the IS but based on work carried out in
asthmatic w10x and COPD w9x populations we would
anticipate that qualitative differences are likely to exist.
IS, at least in asthmatics, is rich in eosinophils and
neutrophils and poor in lymphocytes and macrophages
compared with BAL w10x. As expected we found signif-
icantly more neutrophils in BAL from CF patients when
compared with the healthy subjects and MA.
It is possible that the design of our study in which
patients underwent BAL and IS on consecutive days
may have influenced mediator and cell measurements
or contributed to the adverse events. However, the aim
of this study was not to quantify the effects of sampling
methods on cell or mediator measurements. In any case,
any effect is likely to have been minimised by the
randomised design of the study. Furthermore, Fahy et
al. have demonstrated that BAL sampling immediately
after sputum induction appears safe and does not signif-
icantly influence cell and mediator levels measured in
an isolated BAL sample 1 week earlier w8x.
Bronchoscopy and BAL are generally well tolerated
even when extended to asthmatics with severe disease
w11x. Less is known about the safety of BAL in patients
with CF. While IS appears to be safe when used for
patients with severe airflow limitation, there is no data
on the effects on CF patients. In this study, IS was safe
and well tolerated by all patients. As recommended w12x,
pulmonary function was monitored frequently during
sputum induction and no clinically or statistically sig-
nificant reduction in FEV post sputum induction was1
noted. Adverse events were reported for 3 CF patients
almost immediately following BAL. One patient became
hypoxaemic during bronchoscopy and shortly after
developed a severe pyrexia with an associated rise in
CRP. A high fever lasting 16 h and requiring hospital-
isation was also recorded in another CF patient and a
further patient became dyspnoeic with right mid zone
consolidation on CXR. In contrast, Konstan et al. report-
ed on their BAL findings in clinically mild CF patients
and observed a high fever ()38.5 8C), which they
considered a minor reaction in only 2 of 18 subjects
w1x. In our study, the CF patients had well preserved
lung function. This is broadly representative of our
stable CF population. We suspect that BAL may carry
even greater risk in subjects with more severely impaired
lung function.
Hypoxia during or following bronchoscopy is recog-
nised especially in critically ill patients with compro-
mised gas exchange w13x. Premedication may contribute
to this and may have been the case with our patient
although this does not explain the subsequent systemic
response.
Fever has been reported to follow bronchoscopy and
BAL in between 10 and 30% of cases and is usually
considered a minor reaction w14x. The origin of the
pyrexia is not known although an infectious mechanism
seems possible. In one study of bronchoscopy and BAL,
performed on ventilated patients, fever occurred in 73%
of patients with pneumonia compared with only 17% in
those without w15x. It is notable that only the CF patients
had fever following BAL and as these patients have
chronically infected lower airways, the lavage process
may cause translocation of endotoxin into the circula-
tion. Endotoxins are known to induce release of media-
tors such as TNFa and interleukins, which may be
responsible for the fever w16x.
In summary, IS is an acceptable technique for obtain-
ing airway secretions from patients with CF. It is
relatively non-invasive and when compared with BAL
it may provide a richer source of the cells and mediators
thought to play an important role in the pathophysiology
of CF. Importantly, our observations suggest that even
when performed on adult CF patients with stable disease,
BAL appears a hazardous procedure which cannot be
recommended in the research setting.
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